DexCom stock jumps in premarket after early Q4 sales and 2026 outlook; what DXCM investors watch next
NEW YORK, Jan 13, 2026, 7:52 AM ET — Premarket DexCom shares climbed roughly 5% in premarket action Tuesday, buoyed by new guidance that thrust the diabetes-device company back into focus as earnings season kicks off. (StreetInsider.com) DexCom’s preliminary Q4 update offers investors an early glimpse at 2026 revenue growth, following a stretch where talk around guidance hurt the stock more than actual results. Shares tumbled sharply in late October after execs cautioned that 2026 growth might come in just under current forecasts. (Reuters) Tuesday’s action came amid a nervous market backdrop. U.S. stock index futures slipped slightly before the